Neuland Laboratories Limited has informed the Exchange regarding a press release dated May 12, 2026, titled "Press Release on the Financial Results of the Company for the quarter and year ended March 31, 2026".
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts less than Nifty Smallcap 250 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Neuland Laboratories reported exceptional Q4FY26 results with total income of Rs.788.7 crore, up 134.9% YoY, and EBITDA of Rs.319.4 crore, up 448.6% YoY. EBITDA margin expanded sharply to 40.5% from 17.3% in Q4FY25, a gain of 2316 basis points. Profit after tax rose to Rs.212.5 crore versus Rs.27.7 crore in the prior year quarter. Management noted good short-to-medium-term business visibility anchored by commercial and near-commercial molecules, and said investments in peptide manufacturing and a new R&D centre are proceeding on plan. The company will host an earnings call on May 12, 2026.
The sharp improvement in margins and profitability signals strong operational execution and likely one-time or accelerated revenue recognition; however, the extreme magnitude of the swing warrants scrutiny on sustainability when assessing long-term investment thesis.